Trials / Unknown
UnknownNCT05599802
Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants
An Open-Label, Phase 1 Clinical Study to Determine the Safety and Preliminary Immunogenicity of SARS-CoV-2 Variant mRNA Vaccine (LVRNA010) in Healthy Participants Aged 18 Years and Older
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- AIM Vaccine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
An Open-Label, Phase 1 Clinical Study to Determine the Safety and Preliminary Immunogenicity of SARS-CoV-2 Variant mRNA Vaccine (LVRNA010)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SARS-CoV-2 variant mRNA vaccine low dose | 50μg/dose |
| BIOLOGICAL | SARS-CoV-2 variant mRNA vaccine high dose | 100μg/dose |
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2023-05-01
- Completion
- 2024-05-01
- First posted
- 2022-10-31
- Last updated
- 2022-11-01
Source: ClinicalTrials.gov record NCT05599802. Inclusion in this directory is not an endorsement.